2020
Gene Alterations of N6‐Methyladenosine (m6A) Regulators in Colorectal Cancer: A TCGA Database Study
Zhang Q, Cai Y, Kurbatov V, Khan SA, Lu L, Zhang Y, Johnson CH. Gene Alterations of N6‐Methyladenosine (m6A) Regulators in Colorectal Cancer: A TCGA Database Study. BioMed Research International 2020, 2020: 8826456. PMID: 33415160, PMCID: PMC7769650, DOI: 10.1155/2020/8826456.Peer-Reviewed Original ResearchMeSH KeywordsAdenosineAgedAlpha-Ketoglutarate-Dependent Dioxygenase FTOColorectal NeoplasmsDatabases, GeneticDisease-Free SurvivalDNA Copy Number VariationsFemaleGene Expression Regulation, NeoplasticGenes, NeoplasmHumansMaleMultivariate AnalysisMutationNerve Tissue ProteinsPrognosisProportional Hazards ModelsRNA Splicing FactorsRNA, MessengerConceptsDisease-free survivalImmune cell infiltrationM6A regulatorsCRC patientsCRC casesCell infiltrationMRNA expressionWorse overall survivalN6-methyladenosine regulatorsMicrosatellite instability statusMessenger RNA expressionCancer Genome AtlasOverall survivalColorectal cancerCRC tissuesDatabase studyImmune functionInstability statusColon tissuesRole of m6AGene alterationsRNA expressionCRCGenome AtlasGenetic mutationsHot Spot TERT Promoter Mutations Are Rare in Sporadic Pancreatic Neuroendocrine Neoplasms and Associated with Telomere Length and Epigenetic Expression Patterns
Posch A, Hofer-Zeni S, Klieser E, Primavesi F, Naderlinger E, Brandstetter A, Filipits M, Urbas R, Swiercynski S, Jäger T, Winkelmann P, Kiesslich T, Lu L, Neureiter D, Stättner S, Holzmann K. Hot Spot TERT Promoter Mutations Are Rare in Sporadic Pancreatic Neuroendocrine Neoplasms and Associated with Telomere Length and Epigenetic Expression Patterns. Cancers 2020, 12: 1625. PMID: 32575418, PMCID: PMC7352723, DOI: 10.3390/cancers12061625.Peer-Reviewed Original ResearchTelomerase reverse transcriptase (TERT) promoter mutationsPancreatic neuroendocrine neoplasmsSporadic pancreatic neuroendocrine neoplasmsT allele frequencyC250TNeuroendocrine neoplasmsPNEN casesReverse transcriptase (TERT) promoter mutationsDisease-free survivalTrue clinical valueLarge patient cohortPromoter mutationsTERT promoter mutationsParaffin-embedded tissuesPNEN patientsTPM statusClinicopathological informationPatient cohortClinical valueHigh incidenceCancer subtypesAllele frequenciesRelative TLTelomere maintenance mechanismCancer cells
2015
Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis
Wang Z, Katsaros D, Shen Y, Fu Y, Canuto EM, Benedetto C, Lu L, Chu WM, Risch HA, Yu H. Biological and Clinical Significance of MAD2L1 and BUB1, Genes Frequently Appearing in Expression Signatures for Breast Cancer Prognosis. PLOS ONE 2015, 10: e0136246. PMID: 26287798, PMCID: PMC4546117, DOI: 10.1371/journal.pone.0136246.Peer-Reviewed Original ResearchConceptsBreast cancer prognosisCancer prognosisGene expression signaturesExpression signaturesPoor disease-free survivalDisease-free survivalBreast cancer patientsBreast cancer cell linesBreast cancer progressionMDA-MB-468Tumor cell growthMDA-MB-231Multiple gene expression signaturesCancer cell linesAggressive tumorsCancer patientsClinical significanceDisease outcomeTumor featuresClinical implicationsPrognosisCancer progressionBiologic relevanceHigh expressionCell proliferation
2012
Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC).
deLeon M, Lu L, Hui P, Santin A, Rutherford T, Arin-Silasi D, Azodi M, Ratner E, Schwartz P. Prognostic factors and treatment-related outcomes in patients with uterine serous cancer (USC). Journal Of Clinical Oncology 2012, 30: 5099-5099. DOI: 10.1200/jco.2012.30.15_suppl.5099.Peer-Reviewed Original ResearchStage IA/IBDisease-free survivalUterine serous cancerIIIA/IIIBIVA/IVBIA/IBUSC patientsPrognostic factorsMyometrial invasionLargest single-institution experienceWhole-pelvis radiation therapyLymph node involvementPlatinum-based chemotherapySingle institution experienceIndependent prognostic factorLymph node metastasisTreatment-related outcomesUterine cancer deathsBetter OSII-IVBIB diseaseNode involvementSurgical debulkingSerous cancerShorter OS
2011
Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome
Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, Mitidieri M, Katsaros D, Yu H. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Research 2011, 13: r56. PMID: 21645396, PMCID: PMC3218945, DOI: 10.1186/bcr2893.Peer-Reviewed Original ResearchConceptsEndocrine therapyDisease outcomeAdjuvant treatmentTelomerase expressionBetter survival outcomesDisease-free survivalHormone receptor statusBreast cancer patientsRisk of deathTelomere lengthHigh telomeraseCause-specific mortalityBreast cancer prognosisBreast cancer cellsCancer cell resistanceHigh telomerase expressionOverall survivalPatient ageDisease recurrenceReceptor statusHistological typeAggressive diseaseSurvival outcomesDisease stageCancer patients
2010
Let-7a regulation of insulin-like growth factors in breast cancer
Lu L, Katsaros D, Zhu Y, Hoffman A, Luca S, Marion CE, Mu L, Risch H, Yu H. Let-7a regulation of insulin-like growth factors in breast cancer. Breast Cancer Research And Treatment 2010, 126: 687-694. PMID: 20848182, DOI: 10.1007/s10549-010-1168-5.Peer-Reviewed Original ResearchConceptsIGF expressionBreast cancerOvarian cancerInsulin-like growth factorDisease-free survivalCancer cellsAction of IGFBreast cancer patientsExpression of IGFHigh-grade tumorsIGF-II expressionPR-negative cancerLet-7aQuantitative methylation-specific PCRBreast cancer samplesOverall survivalFavorable prognosisPatient survivalCancer patientsGrade tumorsIGF mRNAsMethylation-specific PCRDisease featuresCancerCancer samples
2008
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Research And Treatment 2008, 117: 131-140. PMID: 18932017, DOI: 10.1007/s10549-008-0219-7.Peer-Reviewed Original ResearchConceptsMiR-21 expressionPoor disease-free survivalHigh miR-21 expressionDisease-free survivalHormone receptor statusHigh miR-21Breast cancerMiR-21Tumor samplesReceptor statusTumor gradeTGF-β1Elevated miR-21 expressionNegative hormone receptor statusProportional hazards regression analysisHigher TGF-β1Lymph node involvementEarly-stage diseaseEarly-stage patientsPrimary breast cancerHazards regression analysisHigh tumor gradeFresh tumor samplesTumor cell growthNode involvement